Effects of Phytolacca acinosa polysaccharides I with different schedules on its antitumor efficiency in tumor bearing mice and production of IL-1, IL-2, IL-6, TNF, CSF activity in normal mice.
Effects of Phytolacca acinosa polysaccharides I (PAP-I), 5 approximately 40 mg/kg in timing of 7 times/wk, 3 times/wk and 1 time/wk on their antitumor efficiency in Sarcoma-180 bearing mice were comparatively investigated. The results confirmed that PAP-I (10 mg/kg, 3 times/wk) reached its optimal antitumor efficiency. Concanavalin A-, lipopolysaccharides-induced lymphocyte proliferation and the IL-2 production were tested in normal mice which were treated with PAP-I, 5 approximately 50 mg/kg in timing of 1 time/wk and 3 times/wk. The results showed that PAP-I could augment lymphocyte proliferation and IL-2 production in the group treated with PAP-I in timing of once a week. However, in the group 3 times/wk, PAP-I could significantly weaken lymphocyte proliferation and IL-2 production. Further studies on IL-1, TNF and IL-6 secreted from macrophages and the level of CSF activity in serum of normal mice with different schedules showed that PAP-I (10 mg/kg, 3 time/wk) was the best one in regulating the production of IL-1, TNF, IL-6 and CSF activity. M-CSF was confirmed in the serum by using monoclonal antibody of IL-3, GM-CSF and polyclonal antibody of M-CSF. These results suggested that the antitumor effect of PAP-I, may be mainly related to its augmenting effect on macrophages in mice.
Wang
H B
HB
Department of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, P.R. China.
Zheng
Q Y
QY
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D003115:Colony-Stimulating Factors / Q000378:metabolism*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000627:therapeutic use; D007375:Interleukin-1 / Q000378:metabolism*; D007376:Interleukin-2 / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism*; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000737:chemistry; D016173:Macrophage Colony-Stimulating Factor / Q000097:blood / Q000145:classification / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D011134:Polysaccharides / Q000008:administration & dosage* / Q000627:therapeutic use*; D012510:Sarcoma 180 / Q000209:etiology* / Q000473:pathology; D013154:Spleen / Q000166:cytology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors; D004365:Drugs, Chinese Herbal; D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D011134:Polysaccharides; D014409:Tumor Necrosis Factor-alpha; D016173:Macrophage Colony-Stimulating Factor